The role of anti-thyroglobulin antibody in treatment and follow up of differentiated thyroid cancer

Creative Commons License

DEMİR F., HASBEK Z., ERSELCAN T., TURGUT B.

The Annals of Clinical and Analytical Medicine, cilt.11, sa.3, 2020 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4328/acam.20042
  • Dergi Adı: The Annals of Clinical and Analytical Medicine
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Anahtar Kelimeler: Anti-Thyroglobulin Antibody, Thyroglobulin, Differentiated Thyroid Cancer, SERUM THYROGLOBULIN LEVELS, PROGNOSTIC VALUE, EARLY PREDICTION, ABLATION, RECURRENCE, LEVEL, RISK, TGAB, RADIOIODINE, THERAPY
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Aim: This study aimed to investigate the role of serum anti-thyroglobulin antibody (anti-TgAb) as a marker to predict the success of radioactive iodine (RAI) ablation therapy in differentiated thyroid cancer (DTC) patients and also investigate the role of anti-TgAb in the follow-up of thyroid cancer. Materials and Methods: One hundred thirteen DTC patients with total thyroidectomy who received RAI ablation therapy enrolled in this retrospective study. The first measurement was performed immediately before ablation therapy (thyroglobulin (Tg)1, anti-TgAb 1). The second measurement was performed just before the whole-body iodine 131 (I-131) scan (WBS) within 6-12 months after ablation (Tg 2, Anti-TgAb 2). Patients were divided into two groups according to ablation success: Group 1 (successful) and Group 2 (unsuccessful). Tg and anti-TgAb levels and the difference between two measurements were compared between groups. Results: In terms of Anti-Tg antibody positivity and the anti-Tg Ab 1 and anti-Tg Ab 2 levels, there was no statistically significant difference between groups (p= 0.661, p = 0.716, p = 0.764, respectively). When the groups were compared in terms of anti-Tg Ab level change after treatment, a statistically significant decrease was observed in Group 1 (p <0.001), but there was no statistically significant decrease in Group 2 (p = 0.277). Discussion: In conclusion, a reduction in anti-Tg Ab level, measured within 6-12 months after the ablation, can be used as an indicator of treatment success.